The study dealt with the search for biomarkers for personalized medicine in morbid obesity. Plasma samples from morbidly obese patients and controls were analyzed using metabolomics. The metabolite LPC 17:0 was identified as a potential biomarker that distinguished patients from controls with 78% accuracy. LPC 17:0 levels were negatively correlated with BMI, suggesting its association with obesity severity. Another metabolite, PC O-40:1, has also shown promise. The findings suggest that LPC 17:0 could serve as a novel biomarker for monitoring the progression of morbid obesity. The study supports the development of personalized medicine approaches for better risk stratification and targeted treatment.